옵션 체인은 다양한 행사가격과 만기일에 대한 Pasithea Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Pasithea Therapeutics에 대한 시장 심리를 평가합니다..

Pasithea Therapeutics (NASDAQ:KTTA) 주식, 옵션 체인

Pasithea Therapeutics

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics Corp

Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 200 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $78.72 million which missed the analyst consensus estimate of $82.75 million by 4.86 percent. This is a 16.70 percent decrease over sales of $94.50 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

ASPN

Aspen Aerogels Q1 Adj. EPS $(0.06) Beats $(0.07) Estimate, Sales $78.72M Miss $82.75M Estimate

WIIM

AOSL

Alpha and Omega Semiconductor shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 sales guidance with its midpoint above estimates.

Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) lowers FY2025 sales outlook from $1.36 billion-$1.40 billion to $1.29 billion-$1.38 billion vs $1.37 billion estimate.

Guidance

ARHS

Arhaus Lowers FY2025 Sales Guidance from $1.36B-$1.40B to $1.29B-$1.38B vs $1.37B Est

GRPN

Groupon shares are trading higher after the company reported better-than-expected Q1 financial results.

Choice Hotels Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>) lowers FY2025 GAAP EPS guidance from $6.04-$6.29 to $5.86-$6.18 vs $6.39 analyst estimate..

Choice Hotels Intl Lowers FY2025 GAAP EPS Guidance from $6.04-$6.29 to $5.86-$6.18 vs $6.39 Est

Choice Hotels Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>) lowers FY2025 Adj EPS guidance from $6.98-$7.24 to $6.90-$7.22 vs $7.04 analyst estimate..

Choice Hotels Intl Lowers FY2025 Adj EPS Guidance from $6.98-$7.24 to $6.90-$7.22 vs $7.04 Est

Full Year 2025 Guidance
The following is our guidance reflecting our updated expectations for revenue and Adjusted EBITDA for the full fiscal year 2025 (year ending January 3, 2026):
<ul>
<li>Revenue of greater than $2.15 billion, updated from a range of $2.10 - $2.12 billion &nbsp;</li>
</ul>
Consistent with prior practice, we are not providing guidance on net income at this time due to the volatility of certain required inputs that are not available without unreasonable efforts, including future fair value adjustments associated with our interest rate swaps and caps.
<ul>
<li>Adjusted EBITDA of greater than $207 million, updated from a range of $190 - $194 million</li>
</ul>

AVAH

Aveanna Healthcare Hldgs FY2025  Revenue Expected To Be Over $2.15B Updated From A Range Of $2.10B- $2.12B Vs. $2.12B Est

Choice Hotels Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>) reported quarterly earnings of $1.34 per share which missed the analyst consensus estimate of $1.37 by 2.19 percent. This is a 4.69 percent increase over earnings of $1.28 per share from the same period last year. The company reported quarterly sales of $332.86 million which beat the analyst consensus estimate of $331.64 million by 0.37 percent. This is a 0.27 percent increase over sales of $331.95 million the same period last year.

Choice Hotels Intl Q1 Adj. EPS $1.34 Misses $1.37 Estimate, Sales $332.86M Beat $331.64M Estimate

Planet Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) affirms FY2025 Adj EPS guidance from $2.87-$2.90 to $2.87-$2.90 vs $2.93 analyst estimate. Affirms FY2025 sales outlook from $1.30 billion to $1.30 billion vs $1.31 billion estimate.

PLNT

Planet Fitness Affirms FY2025 Adj EPS Guidance of $2.87-$2.90 vs $2.93 Est; Affirms FY2025 Sales Guidance of $1.30B vs $1.31B Est

InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) affirms FY2025 sales outlook from $145.65 million-$148.35 million to $145.65 million-$148.35 million vs $146.63 million estimate.

INFU

InfuSystems Holdings Affirms FY2025 Sales Guidance of $145.65M-$148.35M vs $146.63M Est

NCR Voyix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VYX#NYSE">VYX</a>) is looking for FY2025 Adj EPS of $0.75-$0.80 vs $0.91 analyst estimate. Affirms FY2025 sales outlook from $2.58 billion-$2.65 billion to $2.58 billion-$2.65 billion vs $2.21 billion estimate.

NCR Voyix Sees FY2025 Adj EPS $0.75-$0.80 vs $0.91 Est; Affirms FY2025 Sales Guidance of $2.58B-$2.65B vs $2.21B Est

Restaurant Brands Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) reported quarterly earnings of $0.75 per share which missed the analyst consensus estimate of $0.78 by 3.85 percent. This is a 2.74 percent increase over earnings of $0.73 per share from the same period last year. The company reported quarterly sales of $2.11 billion which missed the analyst consensus estimate of $2.13 billion by 0.88 percent. This is a 21.28 percent increase over sales of $1.74 billion the same period last year.

Restaurant Brands Intl Q1 Adj. EPS $0.75 Misses $0.78 Estimate, Sales $2.11B Miss $2.13B Estimate

Veru (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERU#NASDAQ">VERU</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 28.57 percent increase over losses of $(0.07) per share from the same period last year.

VERU

Veru Q2 EPS $(0.05) Beats $(0.06) Estimate

Maximus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMS#NYSE">MMS</a>) raises FY2025 Adj EPS guidance from $5.90-$6.20 to $6.30-$6.60 vs $6.10 analyst estimate. Raises FY2025 sales outlook from $5.20 billion-$5.35 billion to $5.25 billion-$5.40 billion vs $5.30 billion estimate.

Maximus Raises FY2025 Adj EPS Guidance from $5.90-$6.20 to $6.30-$6.60 vs $6.10 Est; Raises FY2025 Sales Guidance from $5.20B-$5.35B to $5.25B-$5.40B vs $5.30B Est

BCE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCE#NYSE">BCE</a>) reported quarterly earnings of $0.48 per share which missed the analyst consensus estimate of $0.62 by 22.58 percent. This is a 9.43 percent decrease over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $4.13 billion which missed the analyst consensus estimate of $5.92 billion by 30.26 percent. This is a 7.38 percent decrease over sales of $4.46 billion the same period last year.

BCE Q1 Adj. EPS $0.48 Misses $0.62 Estimate, Sales $4.13B Miss $5.92B Estimate

Aveanna Healthcare Hldgs Q1 2025 Adj. EPS $0.10 Up From $(0.03) YoY, Sales $559.22M Beat $513.10M Estimate

Telsey Advisory Group analyst Joseph Feldman maintains Holley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLLY#NYSE">HLLY</a>) with a Outperform and lowers the price target from $4.5 to $2.75.

Price Target

Analyst Ratings

HLLY

Telsey Advisory Group Maintains Outperform on Holley, Lowers Price Target to $2.75

Primo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRMB#NYSE">PRMB</a>) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $0.23 by 26.09 percent. The company reported quarterly sales of $1.61 billion which missed the analyst consensus estimate of $1.62 billion by 0.21 percent.

PRMB

Primo Brands Q1 Adj. EPS $0.29 Beats $0.23 Estimate, Sales $1.61B Miss $1.62B Estimate

Spectrum Brands Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) reported quarterly earnings of $0.68 per share which missed the analyst consensus estimate of $1.41 by 51.77 percent. This is a 58.02 percent decrease over earnings of $1.62 per share from the same period last year. The company reported quarterly sales of $675.70 million which missed the analyst consensus estimate of $697.39 million by 3.11 percent. This is a 5.96 percent decrease over sales of $718.50 million the same period last year.

Spectrum Brands Holdings Q2 Adj. EPS $0.68 Misses $1.41 Estimate, Sales $675.70M Miss $697.39M Estimate

NCR Voyix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VYX#NYSE">VYX</a>) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.14 by 35.71 percent. This is a 30.77 percent decrease over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $617.00 million which missed the analyst consensus estimate of $646.34 million by 4.54 percent. This is a 28.42 percent decrease over sales of $862.00 million the same period last year.

NCR Voyix Q1 Adj. EPS $0.09 Misses $0.14 Estimate, Sales $617.00M Miss $646.34M Estimate

Press Releases

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Power Nickel's (TSX.V: PNPN) Hole Delivers "BIG"- Gold Terra (TSX.V: YGT) Developments and Exploration Progress Reported – More Stocks Inside!

Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Health Care

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

Financing

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

KTTA

KTTAW

OGEN

PNPNF

TSXV:PNPN

TSXV:YGT

YGTFF

Aditxt

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Ensysce Biosciences

Galecto

Genprex

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Oragenics

Palisade Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Plus Therapeutics

Palatin Techs

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

SILO Pharma

Synaptogenix

Tharimmune

Theriva Biologics

VivoSim Labs

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

ZyVersa Therapeutics, Inc. - Common Stock

Comments

Pasithea Therapeutics

Pasithea Therapeutics (KTTA) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌